Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca
AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value…
69,810$
-1,86%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals
…
Fusion Pharmaceuticals Stock Soars. It’s Being Acquired by AstraZeneca in $2.4 Billion Deal.
…
Biotech Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover
The company is working on radiopharmaceuticals treatments for cancer.…
AstraZeneca: Der Pharma-Riese bleibt in Sachen M&A sehr aktiv - Aktienanalyse
Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…
AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting
AstraZeneca PLC (LSE:AZN) is acquiring Canadas Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively keep up with Joneses…
AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase
The deal is AstraZenecas second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to…
AstraZeneca will buy Fusion Pharmaceuticals for ~$2B
…
AstraZeneca to Buy Fusion Pharma for Up to $2.4 Billion
AstraZeneca Plc agreed to buy Fusion Pharmaceuticals Inc. for as much as $2.4 billion as it seeks to transform cancer…
AstraZeneca to buy Fusion Pharma for $2 billion in cash By Reuters
AstraZeneca to buy Fusion Pharma for $2 billion in cash…